SGMOQ — Sangamo Therapeutics Share News
0.000.00%
Last trade - 00:00- $18.64m
- -$8.94m
- $39.55m
Brief: Sangamo Therapeutics, Chroma Medicine Announce Agreement To Develop Zinc Finger Proteins For Epigenetic Editing
U.S. STOCKS ON THE MOVE-Activision Blizzard, Tesla, Paramount Global
Sangamo Therapeutics rises on tie-up with Lilly to evaluate drug delivery tech
Brief: Sangamo Therapeutics Announces Research Evaluation And Option Agreement With Prevail
US FDA approves BioMarin's gene therapy for hemophilia A (updated)
US FDA approves BioMarin's gene therapy for hemophilia A
Brief: Sangamo Therapeutics And Voyager Therapeutics Enter License Agreement
U.S. STOCKS ON THE MOVE-Pfizer, Zoom Video, American Airlines
U.S. STOCKS ON THE MOVE-Atea Pharma, Microbot Medical, Krystal
U.S. STOCKS ON THE MOVE-NuScale Power Corp, Foot Locker, Greenhill
Sangamo up on FDA's 'fast track' tag for genetic disorder therapy
Brief: Sangamo Therapeutics Inc - Reducing Its Us Workforce By Approximately 27%, Or Approximately 120 Roles
Sangamo Therapeutics Inc expected to post a loss of 33 cents a share - Earnings Preview
Vertex/CRISPR's gene editing therapy cost effective at $1.9 million - pricing review group (updated)
Vertex/CRISPR's gene editing therapy cost effective at $1.9 million - pricing review group
Freeline's genetic disorder therapy development pause keeps Sangamo ahead - Truist
U.S. STOCKS ON THE MOVE-Cue Health, Charles Schwab, Semtech
U.S. STOCKS ON THE MOVE-Franchise Group, Connect Biopharma, OSI Systems
U.S. STOCKS ON THE MOVE-WestRock, PacWest, Foot Locker